Table 3.
Drug Concentration Ranges
| Minimum (Individual) | Mean (Population's Cmax) | Maximum (Individual) | |
|---|---|---|---|
| Dofetilide | |||
| Plasma, ng/mL | 0.16 | 2.72 | 3.27 |
| Estimated unbound free fraction, nmol/L | 0.1 | 2.2 | 2.6 |
| Relative to population Cmax, % | 6 | 100 | 120 |
| Quinidine | |||
| Plasma, μg/mL | 0.09 | 1.79 | 2.55 |
| Estimated unbound free fraction, nmol/L | 40.0 | 829.4 | 1179.1 |
| Relative to population Cmax, % | 5 | 100 | 142 |
| Ranolazine | |||
| Plasma, μg/mL | 0.01 | 2.30 | 6.49 |
| Estimated unbound free fraction, nmol/L | 11.1 | 1726.7 | 4867.5 |
| Relative to population Cmax, % | 1 | 100 | 282 |
| Verapamil | |||
| Plasma, ng/mL | 1.55 | 130.35 | 368.00 |
| Estimated unbound free fraction, nmol/L | 0.5 | 45.1 | 127.4 |
| Relative to population Cmax, % | 1 | 100 | 282 |
Individual minimums were observed at 24 hours postdose for all drugs. See Figures S6 through S8 for concentration time profiles.